NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2020, Vol. 32 ›› Issue (12): 2040-2050. doi: 10.16333/j.1001-6880.2020.12.008

Previous Articles     Next Articles

Molecular mechanism of Astragalus Radix and Ligustri Lucidi Fructus herb pair in the treatment of Alzheimer's disease based on network pharmacology and molecular docking

CHEN Bo-wei1,YI Jian2,LIU Bai-yan1,3*,TANG Rong-mei1,ZENG Cheng1   

  1. 1Hunan University of Chinese Medicine,Changsha 410208,China; 2The First Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410007,China;3Yiyang Medical College,Yiyang 413000,China

  • Online:2020-12-28 Published:2020-12-24

Abstract:

In order to explore the mechanism of Astragalus Radix (AR) and Ligustri Lucidi Fructus (LLF) herb pair in the treatment of Alzheimer's disease.The active components and predicted targets of AR and LLF were screened out through Traditional Chinese Medicine System Pharmacology database (TCMSP) and then the related target genes of Alzheimer's disease were mined through GEO and Genecards.The active component-target network and protein interaction was constructed by Cytoscape and String database.Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the core genes,and finally the molecular docking analysis of key active components was carried out.The results showed that 21 active components and 41 key genes from AR and LLF were screened out,which were mainly enriched in Alzheimer's disease pathway,AGE-RAGE signal pathway,TNF signal pathway and IL-17 signal pathway.Molecular docking showed that astragaloside,oleanolic acid,kaempferol,quercetin,luteolin and formononetin could well bind to the target.In summary,AR and LLF herb pair have the characteristics of multi-component and multi-target synergistic effect on the treatment of Alzheimer's disease.This study preliminarily predicted its possible molecular mechanism of action,and provided the basis for the follow-up study.

Key words: Astragalus Radix, Ligustri Lucidi Fructus, Alzheimer's disease, network pharmacology, bioinformatics, molecular docking

CLC Number: